A randomized‐controlled trial to evaluate the app‐based multimodal weight loss program zanadio for patients with obesity

Autor: Lena Roth, Madeleine Ordnung, Katarina Forkmann, Nora Mehl, Annette Horstmann
Přispěvatelé: Doctoral Programme in Human Behaviour, O'BRAIN Lab, Department of Psychology and Logopedics
Rok vydání: 2023
Předmět:
Zdroj: Obesity
ISSN: 1930-739X
1930-7381
DOI: 10.1002/oby.23744
Popis: Objective Although the prevalence of obesity is constantly high, the care situation for patients with obesity is still insufficient. The advent of digital, evidence-based therapies to treat obesity could help alleviate this situation. This study therefore aimed at evaluating the effectiveness of the app-based, multimodal weight loss programme zanadio. Methods To examine the effectiveness for sustained weight loss of zanadio, a randomised-controlled trial (DRKS00024415) was conducted between January 2021 and March 2022. 150 adults with obesity were randomised into an intervention group or a control group. While the participants of the intervention group used zanadio for one year, participants in the control group were not allowed to use the app during the study period but were free to start other weight-loss attempts. The primary endpoint weight change (in %) and the secondary endpoints quality of life, well-being, and waist-to-height ratio, were assessed every three months (T0, T1, T2, T3, T4) via telephone interviews and online questionnaires. For the statistical analyses intention-to-treat and per-protocol analyses were performed. Results After 12 months, based on an intention-to-treat analysis, participants of the intervention group lost on average -7.75% (95% CI=[-9.66, -5.84]) of their initial body weight, while the control group showed no weight loss at the end of the study (M=0.00%, [-1.98, 1.99]). Importantly, the intervention group achieved a clinically relevant (< 5%) and significant weight reduction. These results were confirmed by a per-protocol analysis. Moreover, all secondary endpoints improved significantly in the intervention group, with significantly greater improvements in well-being and waist-to-height ratio than in the control group. Conclusion This study showed that adults with obesity who have used zanadio achieved a significant and clinically relevant weight loss within 12 months and further improved other obesity-related health variables compared to a wait-list control group. Limitations of the study are the mainly female sample and the exclusively self-reported outcome measures. Due to its effectiveness and flexible applicability, zanadio represents a low-threshold and widely accessible treatment offer for patients in Germany, that might alleviate the present care gap for patients with obesity.
Databáze: OpenAIRE
Externí odkaz: